Colorectal Cancer: Translating Innovation into Precision Care
Colorectal cancer is cancer that starts in the colon or rectum. The colon and the rectum are parts of the large intestine, which is the lower part of the body’s digestive system. The colon absorbs water and nutrients from the food and stores waste matter (stool). Stool moves from the colon into the rectum before it leaves the body. Colorectal cancer often begins as a growth called a polyp, which may form on the inner wall of the colon or rectum. Some polyps become cancer over time. Finding and removing polyps can prevent colorectal cancer. During digestion, food moves through the stomach and small intestine into the colon.
Download PDF Brochure of Study, Click Here!!
Colorectal cancer may be benign, or non-cancerous, or malignant. A malignant cancer can spread to other parts of the body and damage them. It is the second leading cause of cancer death in women, and the third for men. However, due to advances in screening techniques and improvements in treatments, the death rate from colorectal cancer has been falling.
Symptoms of colorectal cancer include:
- Changes in bowel habits
- Diarrhea or constipation
- A feeling that the bowel does not empty properly after a bowel movement
- Blood in feces that makes stools look black
- Bright red blood coming from the rectum
- Pain and bloating in the abdomen
Know More About the Symptoms of colorectal cance, Click Here
Treatment for colorectal cancer
- Treatment will depend on several factors, including the size, location, and stage of the cancer, whether or not it is recurrent, and the current overall state of health of the patient.
- Treatment options include chemotherapy, radiotherapy, and surgery.
Top Dominating Key Players :
Hoffmann La Roche, Debiopharm Group, Merck KGaA, Vaccinogen BD, AEterna Zentaris, and Keryx Biopharmaceuticals, Inc., Epigenomics AG, Novigenix SA, Clinical Genomics Technologies Pty Ltd., EDP Biotech Corporation, Volitionrx Limited, Abbott Laboratories, Amgen Inc., Bruker Corporation, Quest Diagnostics Incorporated, Natera, Inc., and Guardant Health, Inc among others.
We have categorized the Colorectal Cancer Market based on the below segment and sub segments
The colorectal cancer market, based on the modality, is segmented into diagnosis type, therapy type, and imaging type. In 2018, the diagnosis type segment held the largest market share of the colorectal cancer market. This segment is also projected to dominate the market in 2027 as it emphasizes the need for early recognition of neoplasms, or in the asymptomatic or pre-cancerous stage.